-
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COST BURDEN IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Feb 25, 2026, 14:42 PM -
COST OF CARE AND BUDGET IMPACT OF FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FROM THE MEXICAN PUBLIC PAYER PERSPECTIVE
Feb 25, 2026, 14:42 PM -
COST-UTILITY ANALYSIS OF A NATIONAL LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) LUNG CANCER SCREENING PROGRAM IN JORDAN: A MARKOV SIMULATION STUDY
Feb 25, 2026, 14:42 PM -
THE ECONOMIC COST OF PREVENTABLE BLINDNESS: PROJECTING THE SOCIOECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN CHILE (2017-2032)
Feb 25, 2026, 14:42 PM -
PERFORMANCE OF ADAPTIVE SMART TAGS IN NESTED KNOWLEDGE FOR AUTOMATED EXTRACTION OF STUDY CHARACTERISTICS
Feb 25, 2026, 14:42 PM -
IMPACT OF MEDICATION CLUSTERS ON POST-DISCHARGE ADVERSE DRUG EVENTS AND HEALTHCARE UTILIZATION AMONG OLDER ADULTS
Feb 25, 2026, 14:42 PM -
FIRST-LINE SYSTEMIC TREATMENT PATTERNS IN METASTATIC UROTHELIAL CARCINOMA IN US COMMUNITY ONCOLOGY PRACTICES
Feb 25, 2026, 14:42 PM -
COST SAVINGS OF AN AI-ENABLED DIGITAL TWIN PROGRAM IN PREDIABETES AND HEALTHY WEIGHT MANAGEMENT
Feb 25, 2026, 14:42 PM -
DEVELOPMENT OF AN INDIVIDUAL-LEVEL SIMULATION MODEL TO ASSESS THE COST CONSEQUENCES OF CARDIOVASCULAR-RENAL-METABOLIC SCREENING POLICIES FROM A NATIONAL PAYER AND SOCIETAL PERSPECTIVE
Feb 25, 2026, 14:42 PM -
COST-UTILITY OF FIRST-LINE DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL COMPARED WITH PLACEBO FOR PATIENTS WITH PA/REC: A PARTITIONED SURVIVAL ANALYSIS
Feb 25, 2026, 14:42 PM -
REVIEW OF CEESP ICERS FOR ORPHAN AND NON-ORPHAN TREATMENTS IN FRANCE, 2024 - 2025
Feb 25, 2026, 14:42 PM -
REAL-WORLD TREATMENT PATTERNS AND EFFICACY OF FIRST-LINE THERAPIES IN PATIENTS WITH MET EXON 14 SKIPPING-MUTATED NON-SMALL CELL LUNG CANCER
Feb 25, 2026, 14:42 PM -
THE POTENTIAL EARLY IMPACT OF THE INFLATION REDUCTION ACT ON BUY-SIDE VALUATION METHODOLOGIES AND TRANSACTION STRUCTURING IN THE PHARMACEUTICAL INDUSTRY
Feb 25, 2026, 14:42 PM -
USE OF REAL-WORLD EVIDENCE ON US BRANDED HCP DRUG WEBSITES: AN AI-ENABLED CONTENT ANALYSIS
Feb 25, 2026, 14:42 PM -
INDIRECT TREATMENT COMPARISON OF ODEVIXIBAT AND MARALIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)
Feb 25, 2026, 14:42 PM -
GEOSPATIAL EQUITY AND ECONOMIC IMPLICATIONS OF HEALTH DEVELOPMENT OFFICES IN HUNGARY
Feb 25, 2026, 14:42 PM -
A NOVEL BIOMARKER FOR THE EARLY DETECTION OF DIABETIC KIDNEY DISEASE: A BUDGET IMPACT ANALYSIS
Feb 25, 2026, 14:42 PM -
CAN A GENERATIVE PATIENT JOURNEY FOUNDATION MODEL ALLEVIATE THE BURDEN OF CANCER SCREENING?
Feb 25, 2026, 14:42 PM -
EFFICACY OF CAR T-CELL THERAPY IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Feb 25, 2026, 14:42 PM -
USE ARTIFICIAL INTELLIGENCE TO PREDICT REGULATORY APPROVAL BASED ON PHASE III ONCOLOGY CLINICAL TRIAL PUBLICATIONS
Feb 25, 2026, 14:42 PM
